Covidien expands Sonicision Cordless Ultrasonic Dissection Device portfolio

Commitment to delivering innovative medical technologies creates most versatile cordless ultrasonic offering in the industry

Covidien plc (NYSE:COV) today announced the expansion of its Sonicision™ Cordless Ultrasonic Dissection Device portfolio, following U.S. Food and Drug Administration 510(k) clearance of three additional device lengths: 13 cm, 26 cm, and 48 cm. With the most versatile cordless ultrasonic portfolio in the industry, Covidien now offers surgeons more options when performing pediatric, urological and bariatric procedures on patients of all sizes.

“Covidien is a pioneer in developing energy-based medical devices and the Sonicision system’s groundbreaking cordless technology continues to transform how minimally invasive surgery is performed,” said Chris Barry, president, Advanced Surgical, Covidien. “These new device lengths enable surgeons to use Sonicision technology in a more diverse range of surgical procedures while avoiding the need for cords and separate generators.”

As the only cordless ultrasonic dissection device currently on the market, the Sonicision system gives surgeons complete freedom of movement in the operating room. Increased mobility eliminates the frustration of managing cords in a sterile field and helps to increase procedural efficiencies. In addition, reducing the number of cords in the operating room (OR) contributes to a safer OR and patient experience.

The Sonicision system is used in a wide variety of general, bariatric, colorectal, gynecological and urological surgical procedures. The device’s streamlined design allows a surgeon’s eyes to remain in the surgical field rather than on the instrument. The new device lengths allow surgeons to expand their use of the Sonicision system to an increasing number of procedures, including pediatric colectomy, splenectomy, and appendectomy.